PHARMACOGENOMICS & DRUG RESPONSE

“𝓐𝓭𝓿𝓪𝓷𝓬𝓮𝓼 𝓲𝓷 𝓰𝓮𝓷𝓸𝓶𝓲𝓬𝓼 𝓪𝓻𝓮 𝓻𝓮𝓼𝓱𝓪𝓹𝓲𝓷𝓰 𝓱𝓸𝔀 𝔀𝓮 𝓮𝓿𝓪𝓵𝓾𝓪𝓽𝓮 𝓭𝓻𝓾𝓰 𝓼𝓪𝓯𝓮𝓽𝔂 𝓪𝓷𝓭 𝓮𝓯𝓯𝓮𝓬𝓽𝓲𝓿𝓮𝓷𝓮𝓼𝓼.” - Margaret Hamburg

🧬 Variability in drug response has long been observed in clinical practice, where some patients benefit significantly from a medication while others experience minimal effects or adverse reactions. Pharmacogenomics seeks to explain these differences at the genetic level, thereby supporting the broader goal of personalized medicine.

          🔹 At the core of pharmacogenomics is the understanding that genetic variations, particularly single nucleotide polymorphisms (SNPs), can affect how drugs are absorbed, distributed, metabolized, and excreted. Enzymes involved in drug metabolism, especially those belonging to the cytochrome P450 family, exhibit genetic variability that can lead to differences in drug efficacy & toxicity.

           🔹 Drug response is not solely determined by metabolic enzymes; genetic differences in drug targets, such as receptors & transport proteins, also play a great role. Variations in receptor genes can alter drug binding affinity & downstream signaling, leading to altered pharmacodynamics. For example, genetic differences in beta-adrenergic receptors may influence how patients respond to cardiovascular drugs. Similarly, transport proteins encoded by genes like ABCB1 can affect drug distribution across biological membranes, influencing both efficacy & toxicity.

           🔹 The clinical applications of pharmacogenomics are increasingly evident in areas such as oncology, psychiatry, and infectious diseases. In cancer therapy, pharmacogenomic profiling helps identify patients who are more likely to respond to targeted therapies, thereby improving outcomes & minimizing unnecessary toxicity. In psychiatry, genetic testing can guide the selection of antidepressants or antipsychotics, reducing the trial-and-error approach often associated with these treatments. Furthermore, pharmacogenomics plays a role in preventing adverse drug reactions, which are a significant cause of morbidity and mortality worldwide.

➡️ Despite its promise, the implementation of pharmacogenomics in routine clinical practice faces several challenges. These include the cost of genetic testing, limited access in low-resource settings, and the need for healthcare professionals to be adequately trained in interpreting genetic data.

⚠️ In conclusion, pharmacogenomics represents a transformative advancement in modern medicine by enabling a more individualized approach to drug therapy.

Abubakar Abubakar ✍🏻

• Dunnenberger HM et al. American J Med Genet C. 2015;169C:71-84.

• Caudle KE et al. Clin Pharmacol Ther. 2014;96:542-548.

• Weinshilboum R, Wang L. Nat Rev Drug Discov. 2017;16:669-681.

• Roden DM et al. Ann Intern Med. 2019;170:825-831.

#Pharmacogenomics #PrecisionMedicine #ClinicalGenetics #MolecularMedicine #SNPs #CYP450 #PGT #CRISPR ⚕️